205 related articles for article (PubMed ID: 16121405)
1. SAR by ILOEs: an NMR-based approach to reverse chemical genetics.
Becattini B; Pellecchia M
Chemistry; 2006 Mar; 12(10):2658-62. PubMed ID: 16121405
[TBL] [Abstract][Full Text] [Related]
2. Targeting apoptosis via chemical design: inhibition of bid-induced cell death by small organic molecules.
Becattini B; Sareth S; Zhai D; Crowell KJ; Leone M; Reed JC; Pellecchia M
Chem Biol; 2004 Aug; 11(8):1107-17. PubMed ID: 15324812
[TBL] [Abstract][Full Text] [Related]
3. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy.
Maurer T
Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602
[TBL] [Abstract][Full Text] [Related]
4. Informatics and modeling challenges in fragment-based drug discovery.
Hubbard RE; Chen I; Davis B
Curr Opin Drug Discov Devel; 2007 May; 10(3):289-97. PubMed ID: 17554855
[TBL] [Abstract][Full Text] [Related]
5. NMR techniques for characterization of ligand binding: utility for lead generation and optimization in drug discovery.
Moore JM
Biopolymers; 1999; 51(3):221-43. PubMed ID: 10516573
[TBL] [Abstract][Full Text] [Related]
6. Strategies and methods in the identification of antagonists of protein-protein interactions.
Gadek TR
Biotechniques; 2003 Jun; Suppl():21-4. PubMed ID: 12813901
[TBL] [Abstract][Full Text] [Related]
7. A fragment-based approach for the discovery of isoform-specific p38alpha inhibitors.
Chen J; Zhang Z; Stebbins JL; Zhang X; Hoffman R; Moore A; Pellecchia M
ACS Chem Biol; 2007 May; 2(5):329-36. PubMed ID: 17465519
[TBL] [Abstract][Full Text] [Related]
8. Importance of molecular computer modeling in anticancer drug development.
Geromichalos GD
J BUON; 2007 Sep; 12 Suppl 1():S101-18. PubMed ID: 17935268
[TBL] [Abstract][Full Text] [Related]
9. Solid-state NMR spectroscopy as a tool for drug design: from membrane-embedded targets to amyloid fibrils.
Middleton DA
Biochem Soc Trans; 2007 Nov; 35(Pt 5):985-90. PubMed ID: 17956260
[TBL] [Abstract][Full Text] [Related]
10. Structure-based development of target-specific compound libraries.
Orry AJ; Abagyan RA; Cavasotto CN
Drug Discov Today; 2006 Mar; 11(5-6):261-6. PubMed ID: 16580603
[TBL] [Abstract][Full Text] [Related]
11. SAR by NMR: putting the pieces together.
Hajduk PJ
Mol Interv; 2006 Oct; 6(5):266-72. PubMed ID: 17035667
[TBL] [Abstract][Full Text] [Related]
12. Novel prostaglandin D synthase inhibitors generated by fragment-based drug design.
Hohwy M; Spadola L; Lundquist B; Hawtin P; Dahmén J; Groth-Clausen I; Nilsson E; Persdotter S; von Wachenfeldt K; Folmer RH; Edman K
J Med Chem; 2008 Apr; 51(7):2178-86. PubMed ID: 18341273
[TBL] [Abstract][Full Text] [Related]
13. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
14. Application of NMR methods to identify detection reagents for use in development of robust nanosensors.
Cosman M; Krishnan VV; Balhorn R
Methods Mol Biol; 2005; 300():141-63. PubMed ID: 15657483
[TBL] [Abstract][Full Text] [Related]
15. NMR in drug discovery.
Pellecchia M; Sem DS; Wüthrich K
Nat Rev Drug Discov; 2002 Mar; 1(3):211-9. PubMed ID: 12120505
[TBL] [Abstract][Full Text] [Related]
16. Discovery of novel inhibitors of the ZipA/FtsZ complex by NMR fragment screening coupled with structure-based design.
Tsao DH; Sutherland AG; Jennings LD; Li Y; Rush TS; Alvarez JC; Ding W; Dushin EG; Dushin RG; Haney SA; Kenny CH; Malakian AK; Nilakantan R; Mosyak L
Bioorg Med Chem; 2006 Dec; 14(23):7953-61. PubMed ID: 16919463
[TBL] [Abstract][Full Text] [Related]
17. Non-peptidic small molecule inhibitors of XIAP.
Park CM; Sun C; Olejniczak ET; Wilson AE; Meadows RP; Betz SF; Elmore SW; Fesik SW
Bioorg Med Chem Lett; 2005 Feb; 15(3):771-5. PubMed ID: 15664855
[TBL] [Abstract][Full Text] [Related]
18. The target discovery process.
Egner U; Krätzschmar J; Kreft B; Pohlenz HD; Schneider M
Chembiochem; 2005 Mar; 6(3):468-79. PubMed ID: 15742383
[TBL] [Abstract][Full Text] [Related]
19. Using NMR for ligand discovery and optimization.
Villar HO; Yan J; Hansen MR
Curr Opin Chem Biol; 2004 Aug; 8(4):387-91. PubMed ID: 15288248
[TBL] [Abstract][Full Text] [Related]
20. Ranking poses in structure-based lead discovery and optimization: current trends in scoring function development.
Rajamani R; Good AC
Curr Opin Drug Discov Devel; 2007 May; 10(3):308-15. PubMed ID: 17554857
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
